Good evening :)
$
₹
Delcath Systems Inc

Delcath Systems Inc

DCTH

NASDAQ
Asset Logo

Delcath Systems Inc

DCTH

NASDAQ
$14.581.10% (+0.16)
$
₹
$14.581.10% (+0.16)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Medical Devices

Small Cap

With a market cap of $500.4M the stock is ranked 3281

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

1442
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.69
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$0.01
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

1.59
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0.56%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 5 analysts reports

Buy
5 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+66.44%

Earnings Growth

-292.86%

Rev. Growth

+24.61%

See Detailed Forecast

Company Profile

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.
Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. The company also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1988 and is headquartered in Queensbury, New York.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
Abbott Laboratories
ABT
Abbott Laboratories
P/E Ratio
38.55
38.55
1Y Return
18.86%
18.86%
Buy Reco %
85.71
85.71
Danaher Corporation
DHR
Danaher Corporation
P/E Ratio
38.16
38.16
1Y Return
3.48%
3.48%
Buy Reco %
83.33
83.33
Intuitive Surgical Inc
ISRG
Intuitive Surgical Inc
P/E Ratio
54.69
54.69
1Y Return
17.95%
17.95%
Buy Reco %
76.47
76.47
Medtronic PLC
MDT
Medtronic PLC
P/E Ratio
23.44
23.44
1Y Return
1.27%
1.27%
Buy Reco %
66.66
66.66
Stryker Corporation
SYK
Stryker Corporation
P/E Ratio
31.82
31.82
1Y Return
19.81%
19.81%
Buy Reco %
79.31
79.31
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 66.44% growth, versus a trailing 3-year CAGR of 60.31%.

2026
Current$14.42Baseline
Analyst Target - 1 year
Target$24+66.44%

All values in $

202220232024202520262027$9.03$14.82$20.61Target+66.44%
2026
Current$14.42Baseline
Analyst Target - 1 year
Target$24+66.44%

All values in $

Revenue Forecast

Revenue Forecast

Lower revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 24.61% growth, versus a trailing 3-year CAGR of 215.30%.

2025
Current$85.23Baseline
Forecast for Dec 2026
High$107.8+26.48%
Average$106.21+24.61%
Low$105.21+23.45%

All values in $ Million

2021202220232024202520263.552.712.0637.2085.23Low+23.45%Average+24.61%High+26.48%
2025
Current$85.23Baseline
Forecast for Dec 2026
High$107.8+26.48%
Average$106.21+24.61%
Low$105.21+23.45%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$0.07Baseline
Forecast for Dec 2026
High$-0.01-114.29%
Average$-0.14-292.86%
Low$-0.22-414.29%

All values in $

202120222023202420252026-3.63-3.96-2.97-0.980.07Low-414.29%Average-292.86%High-114.29%
2025
Current$0.07Baseline
Forecast for Dec 2026
High$-0.01-114.29%
Average$-0.14-292.86%
Low$-0.22-414.29%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

20.5
0.8
20.7
-1.8
24.9
-1
29.1
2.6
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue3.137.7611.215.119.7824.1520.5620.7224.9929.13
Net Income-11.11-13.741.86-3.391.062.690.83-1.89-1.072.66
Net Profit Margin-353.96%-176.93%16.64%-22.50%5.40%11.16%4.03%-9.14%-4.28%9.15%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareMedical Devices

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Delcath Systems Inc 14424.691.59
Abbott Laboratories38.553.572.12
Danaher Corporation38.162.951.32
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare DCTH with any stock or ETF
Compare DCTH with any stock or ETF
Comparing from
DCTH
ABT
DHR
Loading...

Frequently asked questions

  1. Delcath Systems Inc (DCTH) share price today is $14.58 as of October 26, 2026 at 11:14 PM IST. The stock touched a day high of $14.73 and a day low of $14.39.

  2. Delcath Systems Inc stock trades on NASDAQ under the ticker symbol DCTH.

  3. Delcath Systems Inc's market capitalization is $500.35M as of October 26, 2026 at 11:14 PM IST.

  4. Delcath Systems Inc's price-to-earnings (P/E) ratio is 1442 as of October 26, 2026.

  5. Delcath Systems Inc's price-to-book (P/B) ratio is 4.69 as of October 26, 2026.

  6. Yes, You can buy Delcath Systems Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Delcath Systems Inc shares in three steps: 1. Search Delcath Systems Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Delcath Systems Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Delcath Systems Inc (DCTH) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.6858 shares at the current price of $14.58.

Loading...